glp 1 sleep apnea GLP-1/Zepbound: Changing the Landscape of Care Episode 75- GLP 1 drugs

Coaching patients to slow injection to 15-20 seconds drops the persistent-lump rate to under 2%

Cagrilintide Cagrilintide is an investigational amylin receptor agonist developed for the treatment of obesity and weight management

Designed for consistent everyday use

However, the comparison of NNT across various drug classes must be nuanced given the NNT values are specific to individual trial design, study population baseline characteristics, and the time of outcome measurement

Safe, cheap interventions which have a sound biological rationale should be prioritized for experimental use in the current context of a global health pandemic